HREBA | Health Research Ethics Board of Alberta

CLINICAL TRIALS COMMITTEE MEMBERSHIP

07 May 2021

Name	Role and Primary Specialty	City
Ann Boerner, MN	Community Member	Calgary
Sunil Desai, MD (Vice Chair)	Scientific (Pediatric Hematology, Oncology)	Edmonton
John Kennedy, MD, FRCPC	Scientific (Psychiatry, Geriatrics, Neuropsychopharmacology)	Edmonton
Albert Mehl, MD	Scientific (Pediatrics)	Black Diamond
Jodi Parrotta, MA, CCRP	Non-Scientific (Regulations)	Edmonton
Nimesh Patel, MPH	Scientific (Quantitative Methodology)	Lethbridge
Cheryl Pollard, RPN, RN, PhD, ANEF	Scientific (Nursing)	Edmonton
Andrew Ross, PhD	Ethics (Clinical Ethics)	Edmonton
T. Edward Vant (Ted), MD	Scientific (Family Medicine)	Calgary
Peter Venner, MD (Chair)	Scientific (Medical Oncology)	Edmonton
Brent Windwick, LLM, QC (Vice-Chair)	Law (Health Law)	Edmonton

The HREBA Clinical Trials Committee (CTC) is constituted and operates in accordance with the:

- Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2);
- Alberta Health Information Act (HIA);
- Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH);
- Health Canada's *Food and Drug Regulations* (FDR), Part C, Division 5.

The committee is registered with the U.S Department of Health and Human Services, Office for Human Research Protections (OHRP), IRB # 00001209.

The HREBA-CTC is one of three committees which comprise the HIA-designated Health Research Ethics Board of Alberta. Since the three committees operate as one Research Ethics Board, members from one committee may attend another committee's meeting when their expertise is required. This ensures that members in attendance have the specific expertise, relevant competence and knowledge necessary to provide an adequate research ethics review of the proposals under consideration.

The majority of the committee members are Canadian citizens or permanent residents under the Immigration and Refugee Protection Act. Members named as Principal Investigators or Co-investigators on a study that is under review do not participate in discussions related to, nor vote on, such studies when they are presented; this applies to initial and continuing reviews.